United States Legal Status and Compounded Peptide Considerations FDAs May 2026 bulk-substance document lists GHK-Cu except for injectable routes of administration as a 503A category 1 substance under evaluation and says FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 about potential inclusion on the 503A bulks list [19]
Contraindications include pregnancy or breastfeeding, active or suspected cancer, and severe liver or kidney disease
[1] There are several studies aimed to clarify the exact mechanism of BPC-157 wound healing
This makes topical serums well-suited for cosmetic use and a potentially valuable part of many professional skincare and hair growth products
Results are natural, subtle yet impactful, and are really long lasting." I love what I do because in aesthetics, art meets science, it blends two worlds that I love and allows me to beautifully and safely restore confidence in people." Outside of work, Kristen is also a fitness instructor
Tirzepatide adds more GLP-1 and GIP activity